Trial Profile
Phase II Study of the Efficacy and Toxicity of Humanized Anti-Tac (Zenapax) in the Therapy of Tac-Expressing Adult T-Cell Leukemia.
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Daclizumab (Primary)
- Indications Leukaemia
- Focus Adverse reactions; Therapeutic Use
- 22 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Feb 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jul 2010 Actual patient number is 34 as reported by ClinicalTrials.gov.